 |
ViaCyte
Last updated: January 20, 2024
Paul Laikind, President and CEO
Country: USA | Funding: $235.5M (+)
Website: http://viacyte.com/
ViaCyte is a leader in the emerging field of regenerative medicine. ViaCyte's innovative product is based on the differentiation of stem cells into pancreatic beta cell precursors, with subcutaneous implantation in a retrievable and immune-protective encapsulation medical device. Once implanted, the precursor cells mature into endocrine cells that secrete insulin and other hormones in a regulated manner to control blood glucose levels. ViaCyte's goal is a product that can free patients with type 1 and type 2 diabetes from long-term insulin dependence.
Website: http://viacyte.com/
ViaCyte is a leader in the emerging field of regenerative medicine. ViaCyte's innovative product is based on the differentiation of stem cells into pancreatic beta cell precursors, with subcutaneous implantation in a retrievable and immune-protective encapsulation medical device. Once implanted, the precursor cells mature into endocrine cells that secrete insulin and other hormones in a regulated manner to control blood glucose levels. ViaCyte's goal is a product that can free patients with type 1 and type 2 diabetes from long-term insulin dependence.
